Skip to main content
. 2021 Jul 22;41(7):BSR20210940. doi: 10.1042/BSR20210940

Table 1. Patient characteristics validation cohort.

All patients (n=192) Moderate illness (n=119) Severe illness (n=73) P-value3 Survivors (n=166) Non-survivors (n=26) P-value4
Age (years) 65 (54–72) 66 (53–73) 64 (57–71) 0.285 64 (53–71) 73 (69–75) <0.001
Sex (n, %)
  Male 133 (69) 79 (66) 54 (74) 0.334 115 (69) 18 (69) 1.000
  Female 59 (31) 40 (34) 19 (26) 51 (31) 8 (31)
BMI (kg/m2) 26.4 (24.0–29.0) 26.0 (23.7–28.9) 26.8 (24.7–29.3) 0.250 26.6 (23.9–29.3) 25.8 (24.0–28.4) 0.651
Comorbidity (n, %)
  Diabetes mellitus 38 (20) 22 (19) 16 (22) 0.580 33 (20) 5 (19) 1.000
  Cardiovascular disease 102 (53) 64 (54) 38 (52) 0.882 84 (51) 18 (69) 0.092
  Pulmonary disease 39 (20) 31 (26) 8 (11) 0.016 31 (19) 8 (31) 0.188
  Malignancy 48 (25) 34 (29) 14 (19) 0.171 41 (25) 7 (27) 0.810
Days of illness at day of sampling (days) 11 (8–15) 10 (8–14) 13 (9–16) 0.022 11 (8–15) 11 (8–17) 0.882
ICU admission (n, %)1 73 (38) NA NA NA 57 (34) 16 (62) 0.010
Hospital length of stay (days) 9 (6–24) 7 (5–9) 31 (19–45) <0.001 9 (6–24) 15 (6–15) 0.339
Mortality (n,%) 26 (14) 10 (8) 16 (22) 0.010 NA NA NA
sTREM-1 (pg/ml) 208 (151–292) 195 (139–283) 235 (176–319) 0.017 199 (142–278) 326 (207–445) <0.001
CRP (mg/l) 109 (60–173) 81 (41–120) 175 (128–291) <0.001 103 (56–172) 139 (83–210) 0.154
Ferritin (µg/l) 1058 (543–1879) 822 (399–1461) 1694 (935–2554) <0.001 996 (491–1864) 1270 (717–1962) 0.237
IL-6 (pg/ml)2 72 (28–118) 43 (23–82) 144 (79–405) <0.001 67 (26–104) 188 (70–480) <0.001

Data are presented as median (IQR) or n (%). Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; ICU, intensive care unit; IL-6, interleukin-6; sTREM-1, soluble Triggering receptor Expressed on Myeloid cells 1.

1

ICU admission during total hospital admission.

2

measured in 151 of the 192 patients.

3moderate versus severe illness (Mann–Whitney U test).

4

survivors versus non-survivors (Mann–Whitney U test).